TY - JOUR
T1 - Intrinsic axonal degeneration pathways are critical for glaucomatous damage
AU - Howell, Gareth R.
AU - Soto, Ileana
AU - Libby, Richard T.
AU - John, Simon W.M.
N1 - Funding Information:
The authors thank Robert Nickells for helpful discussions, and K. Saidas Nair, Krish Kizhatil and Mimi de Vries for critical comments. This work was supported by EY011721 (SWMJ), EY018606 (RTL), The Glaucoma Foundation (RTL, GRH), American Health Assistance Foundation (GRH), Glaucoma Research Foundations (GRH), and Research to Prevent Blindness unrestricted grant to the Department of Ophthalmology at the University of Rochester. SWMJ is an Investigator of the Howard Hughes Medical Institute.
PY - 2013/8
Y1 - 2013/8
N2 - Glaucoma is a neurodegenerative disease affecting 70million people worldwide. For some time, analysis of human glaucoma and animal models suggested that RGC axonal injury in the optic nerve head (where RGC axons exit the eye) is an important early event in glaucomatous neurodegeneration. During the last decade advances in molecular biology and genome manipulation have allowed this hypothesis to be tested more critically, at least in animal models. Data indicate that RGC axon degeneration precedes soma death. Preventing soma death using mouse models that are mutant for BAX, a proapoptotic gene, is not sufficient to prevent the degeneration of RGC axons. This indicates that different degeneration processes occur in different compartments of the RGC during glaucoma. Furthermore, the Wallerian degeneration slow allele (Wlds) slows or prevents RGC axon degeneration in rodent models of glaucoma. These experiments and many others, now strongly support the hypothesis that axon degeneration is a critical pathological event in glaucomatous neurodegeneration. However, the events that lead from a glaucomatous insult (e.g. elevated intraocular pressure) to axon damage in glaucoma are not well defined. For developing new therapies, it will be necessary to clearly define and order the molecular events that lead from glaucomatous insults to axon degeneration.
AB - Glaucoma is a neurodegenerative disease affecting 70million people worldwide. For some time, analysis of human glaucoma and animal models suggested that RGC axonal injury in the optic nerve head (where RGC axons exit the eye) is an important early event in glaucomatous neurodegeneration. During the last decade advances in molecular biology and genome manipulation have allowed this hypothesis to be tested more critically, at least in animal models. Data indicate that RGC axon degeneration precedes soma death. Preventing soma death using mouse models that are mutant for BAX, a proapoptotic gene, is not sufficient to prevent the degeneration of RGC axons. This indicates that different degeneration processes occur in different compartments of the RGC during glaucoma. Furthermore, the Wallerian degeneration slow allele (Wlds) slows or prevents RGC axon degeneration in rodent models of glaucoma. These experiments and many others, now strongly support the hypothesis that axon degeneration is a critical pathological event in glaucomatous neurodegeneration. However, the events that lead from a glaucomatous insult (e.g. elevated intraocular pressure) to axon damage in glaucoma are not well defined. For developing new therapies, it will be necessary to clearly define and order the molecular events that lead from glaucomatous insults to axon degeneration.
UR - http://www.scopus.com/inward/record.url?scp=84879844121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879844121&partnerID=8YFLogxK
U2 - 10.1016/j.expneurol.2012.01.014
DO - 10.1016/j.expneurol.2012.01.014
M3 - Review article
C2 - 22285251
AN - SCOPUS:84879844121
SN - 0014-4886
VL - 246
SP - 54
EP - 61
JO - Experimental Neurology
JF - Experimental Neurology
ER -